Adagene Inc
Adagene maintains a strong liquidity position with $74.5 million in cash and equivalents, significantly exceeding its total liabilities of $26.4 million, resulting in a current ratio of 3.07. The company's liquidity_fpt score indicates a low liquidity risk, supported by its high cash reserves relative to its operating cash outflows of -$15.7 million. The company's profitability remains negative, with a net loss of $17.6 million and an operating loss of $21.4 million. Its return on equity of -33.9% and return on assets of -22.5% are below the industry_config preferred metrics for biotechnology firms, which typically emphasize R&D investment over short-term profitability. Adagene's performance is in line with the cohort median for early-stage biotech companies, which often report negative returns during R&D-intensive phases. Adagene's revenue is concentrated in a single business segment, with no disclosed geographic breakdown. The company does not report revenue by geographic region, making it difficult to assess exposure to regional market risks. However, its primary operations are based in the United States, and it is listed on the NASDAQ, indicating a focus on North American mar
Business. Adagene Inc (ADAG.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Adagene Inc (ADAG.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Adagene maintains a strong liquidity position with $74.5 million in cash and equivalents, significantly exceeding its total liabilities of $26.4 million, resulting in a current ratio of 3.07. The company's liquidity_fpt score indicates a low liquidity risk, supported by its high cash reserves relative to its operating cash outflows of -$15.7 million.
The company's profitability remains negative, with a net loss of $17.6 million and an operating loss of $21.4 million. Its return on equity of -33.9% and return on assets of -22.5% are below the industry_config preferred metrics for biotechnology firms, which typically emphasize R&D investment over short-term profitability. Adagene's performance is in line with the cohort median for early-stage biotech companies, which often report negative returns during R&D-intensive phases.
Adagene's revenue is concentrated in a single business segment, with no disclosed geographic breakdown. The company does not report revenue by geographic region, making it difficult to assess exposure to regional market risks. However, its primary operations are based in the United States, and it is listed on the NASDAQ, indicating a focus on North American markets.
The company's growth trajectory is uncertain, with no revenue growth reported in the latest period. The outlook for the current fiscal year does not indicate a significant change in revenue direction, and no numeric deltas are provided for the next fiscal year. Adagene's operating cash flow remains negative, and its free cash flow is -$17.2 million, suggesting continued reliance on external financing for operations.
Risk assessment indicates a low dilution risk, with no immediate filing-based flags detected. The company's shares outstanding remain unchanged between basic and diluted shares, and no recent equity issuance or ATM/shelf registration activity has been reported. The debt-to-equity ratio of 0.12 suggests a conservative capital structure with minimal leverage.
Recent events include the company's continued focus on clinical development of its pipeline, including the advancement of its PD-1/CTLA-4 bispecific antibody, ADG126. No major regulatory or legal events were reported in the latest filings, and the company has not disclosed any material changes in its business strategy or operations.
- Adagene maintains a strong liquidity position with $74.5 million in cash and equivalents.
- The company is currently unprofitable, with a net loss of $17.6 million and a return on equity of -33.9%.
- Adagene's revenue is concentrated in a single business segment, with no geographic breakdown disclosed.
- The company's growth trajectory is uncertain, with no reported revenue growth and negative operating and free cash flows.
- Adagene has a low dilution risk, with no recent equity issuance or ATM/shelf registration activity reported.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Adagene Inc Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,00 %$2M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 3.07xDerived (calculated)
- Return on assets (FY 2025-12-31): -22.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 49.2%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 7,332.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 49.2%Derived (calculated)
- Return on equity (FY 2025-12-31): -49.8%Derived (calculated)
- Net margin (FY 2025-12-31): -229.6%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 47.3%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.75xDerived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -32.0%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 40.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 47.3%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -12.5%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -30.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -12.3%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -23.4%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 172.7%Derived (calculated)
- Net income (annual): USD -17.61MSEC XBRL filing
- Long-term debt (annual): USD 1.14MSEC XBRL filing
- Shareholders' equity (annual): USD 35.35MSEC XBRL filing
- Total liabilities (annual): USD 26.36MSEC XBRL filing
- Cash & equivalents (annual): USD 74.52MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Pre-tax income (annual): USD -17.91MSEC XBRL filing